A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

Inclusion Criteria Concurrent Medication: Allowed: * Stable maintenance or prophylaxis therapy for opportunistic infection, if such therapy was administered for at least 30 days prior to study entry. * Isoniazid for chemoprophylaxis against Mycobacterium tuberculosis. * Fluconazole for mucosal candidiasis or cryptococcosis. * Acyclovir (up to 1.0 g/day). * Dapsone. * Ketoconazole. * Quinolones. * Tetracycline. * Vitamins and herbal therapies. * Antibiotics as clinically indicated. * Systemic corticosteroids for \< 21 days for acute problems. * Regularly prescribed medications. Patients must have: * HIV positivity by ELISA confirmed by Western blot. * CD4 count \< 500 cells/mm3 within 30 days prior to study entry. * No active opportunistic infections requiring treatment (patients on stable maintenance and prophylaxis therapy for opportunistic infections for at least 30 days are permitted). NOTE: * Enrollment of women is encouraged. Prior Medication: Allowed: * Prior stable maintenance or prophylaxis therapy for opportunistic infection, if administered for at least 30 days prior to study entry. Exclusion Criteria Concurrent Medication: Excluded: * Concurrent rifampin or rifabutin. * Other anti-HIV drugs and investigational agents. * Biological response modifiers. * Ganciclovir or foscarnet. * Systemic cytotoxic chemotherapy. Concurrent Treatment: Excluded: * Concurrent radiation therapy other than limited localized therapy to the skin. Patients with the following prior conditions are excluded: * History of peripheral neuropathy. * History of pancreatitis or active liver disease. Prior Medication: Excluded: * Prior ddI. * Ribavirin within 60 days prior to study entry. * AZT or ddC within 2 weeks prior to study entry. Prior Treatment: Excluded: * Transfusion within 2 weeks prior to study entry. Active alcohol abuse.